Provided by Tiger Fintech (Singapore) Pte. Ltd.

Y-mAbs Therapeutics, Inc.

4.01
-0.1250-3.03%
Volume:23.16K
Turnover:93.56K
Market Cap:181.10M
PE:-5.98
High:4.09
Open:4.09
Low:3.94
Close:4.13
Loading ...

Y-mAbs Revenue Outlook: For 2025 Expected Between $75M - $90M Vs. $104.537M Est.; For Q1, Expected Between $18M - $21M Vs. $24.37M Est.

Benzinga
·
04 Mar

Y-mAbs Therapeutics Inc: Qtrly Loss per Share $0.15

THOMSON REUTERS
·
04 Mar

Y-mAbs Therapeutics Inc: Cash and Cash Equivalents Anticipated to Be Sufficient to Fund Operations as Currently Planned Into 2027

THOMSON REUTERS
·
04 Mar

Y-mAbs Therapeutics Inc - 2025 Anticipated Total Revenues Expected to Be Between $75 Mln and $90 Mln

THOMSON REUTERS
·
04 Mar

Y-mAbs Therapeutics Q4 Product Revenue USD 26.5 Million

THOMSON REUTERS
·
04 Mar

Y-mAbs Therapeutics Inc Q1 REV View $24.4 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
04 Mar

Y-mAbs announces publication of Phase 2 interim results on naxitamab

TIPRANKS
·
03 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
03 Mar

Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Zacks
·
25 Feb

Y-Mabs Therapeutics (YMAB) Receives a Buy from Truist Financial

TIPRANKS
·
12 Feb

Y-Mabs Therapeutics (YMAB) Gets a Hold from Bank of America Securities

TIPRANKS
·
11 Feb

YmAbs Therapeutics (YMAB) Loses -26.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks
·
03 Feb

Y-mAbs Presents Translational Pharmacokinetics of GD2-Sada From Pretargeted Rit Platform at the Snmmi Mid-Winter and Acnm Annual Meeting

THOMSON REUTERS
·
31 Jan

Y-Mabs Therapeutics (YMAB) Gets a Hold from Bank of America Securities

TIPRANKS
·
16 Jan

Y-mAbs Therapeutics Price Target Maintained With a $22.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Jan

Y-Mabs Therapeutics (YMAB) Receives a Buy from H.C. Wainwright

TIPRANKS
·
13 Jan

BUZZ-Y-mAbs Therapeutics falls on plans to create two business units

Reuters
·
11 Jan

Benign Growth For Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Underpins Stock's 26% Plummet

Simply Wall St.
·
11 Jan

JonesTrading Sticks to Their Buy Rating for Y-Mabs Therapeutics (YMAB)

TIPRANKS
·
11 Jan

Y-mAbs Therapeutics Establishing Two New Business Units, Reports 2024 Preliminary Net Revenue

MT Newswires Live
·
11 Jan